What the FDA labels say about taking them together
Dihydroergotamine and fosamprenavir
Fosamprenavir's FDA label of September 15, 2023 names dihydroergotamine in its contraindications section; the dihydroergotamine labels PlainMeds reads (4) do not name fosamprenavir. The fosamprenavir label: “Coadministration is contraindicated due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.”
Check it at the source: the dihydroergotamine FDA label on DailyMed (effective March 6, 2025, Oceanside Pharmaceuticals); the fosamprenavir FDA label on DailyMed (effective September 15, 2023, Mylan Pharmaceuticals Inc.).
What does the dihydroergotamine label say about fosamprenavir?
Dihydroergotamine's label (effective March 6, 2025) and its 3 other brand-application labels do not name fosamprenavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Dihydroergotamine Mesylate), NDA020148 (Bausch), as published by Oceanside Pharmaceuticals, effective March 6, 2025 (SPL set 977de209-c53a-4cb4-9f3f-1e850600a9dc), via openFDA; the full label on DailyMed
What does the fosamprenavir label say about dihydroergotamine?
Fosamprenavir label, contraindicationsRifampin o Antipsychotic: Lurasidone (with ritonavir ), pimozide o Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine o GI motility agent:
Fosamprenavir label, drug interactionsConcomitant Drug Class/Drug Name: Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine; Effect on Concentration of Amprenavir or Concomitant Drug: ↑ Ergot derivatives; Clinical Comment: Coadministration is contraindicated due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues [see ].
Source: FDA drug label (Fosamprenavir Calcium), Mylan Pharmaceuticals Inc., effective September 15, 2023 (SPL set 3a1424d8-844c-4e24-9ebd-b2c2b61b61a3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dihydroergotamine | Fosamprenavir | |
|---|---|---|
| Labeled for | Migraine | HIV |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $29.44 per mL 4 mg/mL nasal spray | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once